Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical versus combined topical and systemic treatment for mild diabetic foot ulcer infection
IRCT20230629058615N12Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mupirocin and cefalexin in diabetic foot infection (DFI) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Wound size, C-reactive protein and 3 more. Started Dec 2025; status: completed.
02
Drugs
mupirocincefalexin
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on IRCT20230629058615N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230629058615N12.